the Effect of Integrated Neuomuscular Inhibition Technique on Adult Females With Cervicogenic Headache

Kafrelsheikh University

Status: Completed

Conditions: Cervicogenic Headache

Treatments: Other: integrated neuromuscular inhibition technique; Drug: Muscle relaxants tizanidine

Study type: Interventional

Funder types: Other

Identifiers

NCT07025187

KFSIRB200-612

Details and patient eligibility

About

The purpose of the current study is investigating the effect of integrated neuromuscular inhibition technique on adult females with cervicogenic headache.

Methods: Forty females with cervicogenic headache will be recruited. Patients will be randomly assigned into two groups, group A and group B . Patients in both groups will receive a traditional medical treatment, but group (B) will receive additional integrated neuromuscular inhibition technique.

Full description

Measurements will be taken for all participants before the start of treatment program then after the end of 4 weeks treatment program, then after another 4 weeks of follow up.all patients will be evaluated for headache pain intensity, cervicogenic headache frequency, cervicogenic headache duration, cervical range of motion in all directions, the isometric endurance capacity of sternocledomastoid and anterior scalene, kinesiophobia, neck disability, and headache impact test-6.

All patients will receive a traditional medical program by an experienced neurologist in the form of Muscle relaxants tizanidine ,4 mg to 32 mg, Three times a day.

Patients in experimental group (B) will receive the same program as control group (A) plus the INIT for upper trapezius and suboccipital muscles. The INIT program will be administrated three times a week for one month.

Enrollment: 40 patients

Sex: Female

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1 - A diagnosis of CGH will be made by an experienced neurologist as per the International Classification of Headache Disorders 3rd edition (ICHD-3) , but not including occipital nerve blockage 2-Additional inclusion criteria will include female patients aged> 18 years and<60 years.

3-headache intensity ≥ 3 on eleven-point numerical rating scale at enrolment. 4-at least three-month history of headache with a mean frequency of > 1/week. 5-hypomobility of the upper cervical spine (C0 to C3) on manual examination; and reproduction of the headache on palpation of the upper cervical spine (C0 to C3).

6-In addition, patients should exhibit active trigger points within the suboccipital, and upper trapezius muscles, ipsilaterally over the symptomatic side reproducing their headache symptoms .

Exclusion criteria

• Patients will be excluded if they have any of the following:

  1. cervical radiculopathy,
  2. history of neck, shoulder trauma or surgery,
  3. history of intervention for head or neck pain within the previous 3 months,
  4. A diagnosis of other types of headaches using the criteria of ICHD-3.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

40 participants in 2 patient groups

Control group

Other group

Description:

All patients will receive a traditional medical program by an experienced neurologist in the form of Muscle relaxants tizanidine ,4 mg to 32 mg, Three times a day.

Treatment:

Drug: Muscle relaxants tizanidine

experimental group

Experimental group

Description:

Patients in experimental group (B) will receive the same program as control group (A) plus the INIT for upper trapezius and suboccipital muscles. The INIT program will be administrated three times a week for one month.

Treatment:

Drug: Muscle relaxants tizanidine

Other: integrated neuromuscular inhibition technique